Fimvo’s Strategy 2026–2028 is built on Patient Safety, Collaboration, and Leadership
Fimvo has published its updated strategy for 2026–2028, built on three strong pillars: patient safety, collaboration, and leadership. The strategy aims to strengthen Fimvo’s role as a safeguard and developer of a safe medicine supply chain in Finland and as part of the European medicines verification community.
1. Patient Safety
Fimvo enhances overall public safety by being a key part of a secure medicine supply chain. The medicines verification system prevents falsified medicines from entering legal distribution channels and supports safe medication practices. Pharmacies and other supply chain actors verify package information before dispensing medicines, reducing the risk of medication errors and reinforcing trust in genuine medicines.
2. Collaboration
Fimvo continues close cooperation with supply chain stakeholders and supports system users in fulfilling regulatory requirements. Fimvo provides authorities with reports and information to improve supply reliability and assists in investigating falsified cases. International collaboration, especially within the European medicines verification community, ensures that the needs and perspectives of the Finnish supply chain are heard.
3. Leadership
Fimvo leverages the Finnish supply chain’s advantages and acts as an active communicator to stakeholders, authorities, and citizens. The medicines verification system is well implemented, and its contribution to patient safety is credible. Fimvo invests in operational excellence and ensures that financial investments in the system deliver the best possible outcomes and benefits for all parties.
The new strategy guides Fimvo towards an even safer, more collaborative, and impactful medicine supply chain. With this strategy, Fimvo strengthens its position as a frontrunner in safeguarding the legal medicine supply chain and inspires the entire pharmaceutical community to develop safety and trust in medicine distribution. Read the full strategy below.